Sugi Predict

Sugi Predict / Compounds / SCHEMBL3039002

SCHEMBL3039002

SCHEMBL3039002

Cc1ncnc2c1ncn2[C@@H]1O[C@H](CN)[C@@H](O)[C@H]1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DOT1L Q8TEK3 3/20 0.61
▸ ADORA1 P30542 2/20 0.61
▸ DPP4 P27487 1/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ SLC28A1 O00337 1/20 0.61
▸ MAP3K7 O43318 1/20 0.61
▸ SLC28A2 O43868 1/20 0.61
▸ GAPDH P04406 1/20 0.61
▸ ADORA3 P0DMS8 1/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ ADORA2A P29274 1/20 0.61
▸ ADORA2B P29275 1/20 0.61
▸ STAT6 P42226 1/20 0.61
▸ PI4KA P42356 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ PI4K2B Q8TCG2 1/20 0.61
▸ SLC29A1 Q99808 1/20 0.61
▸ PI4K2A Q9BTU6 1/20 0.61
▸ SLC28A3 Q9HAS3 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8214557 0.89 SLC29A1 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL20419310 0.89 SLC29A1 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL2404574 0.89 SLC29A1 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL7102267 0.89 SLC29A1 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL17612281 0.89 SLC29A1 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL23982476 0.89 SLC29A1 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL1682931 0.89 SLC29A1 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL13777066 0.89 DPP4 (0.59) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL2052404 0.89 SLC29A1 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL4524322 0.89 SLC29A1 (0.73) DOT1LADORA1DPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1898956-A4 ANTI-TUMORAL COMPOSITIONS AND METHODS UAB RESEARCH FOUNDATION (US) 2008-07-23 — — EP claimed
EP-1898956-A2 ANTI-TUMORAL COMPOSITIONS AND METHODS UAB Research Foundation (US) 2008-03-19 — — EP claimed
WO-2006124847-A2 ANTI-TUMORAL COMPOSITIONS AND METHODS UAB RESEARCH FOUNDATION (US) 2006-11-23 — — WO claimed
EP-2331115-B3 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS UAB RES FOUND (US) 2018-12-05 — — EP disclosed
EP-3150220-A1 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS The UAB Research Foundation (US) 2017-04-05 — — EP disclosed
EP-2331115-B1 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS UAB RESEARCH FOUNDATION (US) 2016-10-05 — — EP disclosed
US-20160022784-A1 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS CORNELL UNIVERSITY 2016-01-28 — — US disclosed
US-20140199285-A1 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS SOUTHERN RESEARCH INSTITUTE (US) 2014-07-17 — — US disclosed
WO-2010019954-A9 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS THE UAB RESEARCH FOUNDATION (US) 2010-08-12 — — WO disclosed
US-20100151572-A1 ANTI-TUMORAL COMPOSITIONS METHODS NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR 2010-06-17 — — US disclosed
WO-2010019954-A2 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS THE UAB RESEARCH FOUNDATION (US) 2010-02-18 — — WO disclosed
EP-1898956-A4 ANTI-TUMORAL COMPOSITIONS AND METHODS UAB RESEARCH FOUNDATION (US) 2008-07-23 — — EP disclosed
EP-1898956-A2 ANTI-TUMORAL COMPOSITIONS AND METHODS UAB Research Foundation (US) 2008-03-19 — — EP disclosed
WO-2006124847-A2 ANTI-TUMORAL COMPOSITIONS AND METHODS UAB RESEARCH FOUNDATION (US) 2006-11-23 — — WO disclosed
US-7037718-B2 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof CORNELL RESEARCH FOUNDATION, INC. (US) 2006-05-02 — — US disclosed
EP-1444335-A4 MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF UAB RESEARCH FOUNDATION (US) 2006-03-08 — — EP disclosed
US-20050214901-A1 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION 2005-09-29 — — US disclosed
EP-1444335-A2 MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF UAB Research Foundation (US) 2004-08-11 — — EP disclosed
US-20030228576-A1 Nucleotide sequence coding for a cleaving enzyme; can use in conjuction with substrate to produce toxins which impair abnormal cell growth; antitumor agents NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-12-11 — — US disclosed
WO-2003035012-A2 MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF UAB RESEARCH FOUNDATION (US) 2003-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050214901-A1 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof PNP, UPP1, TYMP DOT1L 4794/4885ADORA1 1213/4885DPP4 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.